India Pharma Outlook Team | Tuesday, 27 May 2025
Key Takeaways:
Oxford Brain Diagnostics (OBD) aims to change neurodegenerative disease diagnosis with its patented Cortical Disarray Measurement (CDM) technology.
Using standard MRI scans, our software provides accurate and objective assessments of brain health. It also strengthens the ability to diagnose neurodegenerative diseases, particularly in cases of Alzheimer.
Also read: Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India
After receiving FDA 510(k) and UKCA self-certification, OBD is now commercialising its technology in the health-care markets across the UK and US. Our intention is to make neurodegeneration diagnosis worldwide quicker and more effective, by allowing for early diagnosis and better monitoring of neurodegenerative diseases such as Alzheimer.
Established in 2019 by former Oxford neuroscience professor Dr. Steven Chance and neuroimaging expert Professor Mark Jenkinson, the OBD CDM received FDA Breakthrough Device Designation in 2020 for its potential to assess adults at risk of Alzheimer's. In 2023, OBD raised multi-million funding from BGF alongside existing investors, in support of regulatory approval and commercial rollout.
Dr. Chance highlighted an urgent need for non-invasive and exact diagnostic tools, while millions of neurodegenerative diseases ravage the earth. Hence, Invest Maggy Lau of BGF lauds OBD for its fast track to development and its great potential for impact.
With new anti-amyloid Alzheimer's drugs on the horizon, OBD's technology is apt for early diagnosis, drug trials, and drug development. The platform is also showing promise in diagnosing Parkinson and multiple sclerosis, thus broadening its clinical opportunities.
, CDSCO.jpg)
